ArticleMolecular cancer therapeutics2018
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Abstract read
In one paragraph
Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels.Frontiers in oncology · 2022Pooled it
- CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.Nature communications · 2022Trial
- Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage.Journal of cellular and molecular medicine · 2026Article
- Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.Journal of the National Cancer Institute · 2026Article
- New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy.Journal of pharmaceutical analysis · 2025Review
- Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.Signal transduction and targeted therapy · 2025Review
- Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors.Current cancer drug targets · 2025Review
- Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer.Breast cancer (Dove Medical Press) · 2025Review
- CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.Cell reports. Medicine · 2024Article
- Comparison of the Response to Neoadjuvant Therapy Between Immunohistochemistry HER2 (3+) and HER2 (2+)/ISH+ Early-Stage Breast Cancer: A Retrospective Multicenter Cohort Study.The oncologist · 2024Article
- Article
- CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer.Scientific reports · 2024Article
- ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.The journal of pathology. Clinical research · 2024Article
- Identification of a gene expression signature associated with breast cancer survival and risk that improves clinical genomic platforms.Bioinformatics advances · 2023Article
- CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma.Nature communications · 2022Article
- Review
- Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status.BMC medicine · 2022Article
- Breast cancer in the era of integrating "Omics" approaches.Oncogenesis · 2022Review
- MiR-155 deficiency protects renal tubular epithelial cells from telomeric and genomic DNA damage in cisplatin-induced acute kidney injury.Theranostics · 2022Article
- StableFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Kalnisha NaidooThe Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Patty T WaiThe Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Sarah L MaguireThe Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Frances DaleyThe Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Syed HaiderThe Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Divya KriplaniThe Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
James CampbellThe Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Hasan MirzaCancer Bioinformatics, Cancer Division, King's College London, London, United Kingdom.
Anita GrigoriadisCancer Bioinformatics, Cancer Division, King's College London, London, United Kingdom.
Andrew TuttThe Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Paul M MoseleyClinical Oncology, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom.
Tarek M A Abdel-FatahClinical Oncology, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom.
Stephen Y T ChanClinical Oncology, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom.
Srinivasan MadhusudanDepartment of Histopathology and Division of Cancer & Stem Cells, School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom.
Emad A RhakaDepartment of Histopathology and Division of Cancer & Stem Cells, School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom.
Ian O EllisDepartment of Histopathology and Division of Cancer & Stem Cells, School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom.
Christopher J LordThe Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Yinyin YuanDivision of Molecular Pathology, Centre for Evolution and Cancer and Centre for Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.
Andrew R GreenDepartment of Histopathology and Division of Cancer & Stem Cells, School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom.
Rachael NatrajanThe Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom. rachael.natrajan@icr.ac.uk.
Funding
Breast Cancer Now 2011MAYSF01Cancer Research UK 14276Cancer Research UK 24439
Abstract
Disruption of Cyclin-Dependent Kinase 12 (
Indexed as
DNA DamageBiomarkers, TumorBreast NeoplasmsCyclin-Dependent KinasesFemaleHumansImmunohistochemistryMiddle AgedRetrospective StudiesBiomarkers, TumorCDK12 protein, humanCyclin-Dependent Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.